Quantum BioPharma Ltd (fra:0K91) Share Price

Company Profile

Business description
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Contact
1 Adelaide Street East
Suite 801
TorontoONM5C 2V9
CAN
T: +1 416 854-8884
https://www.quantumbiopharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7

Recommended

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,935.00	14.40	-0.16%
CAC 40	8,104.09	37.83	-0.46%
DAX 40	24,018.26	65.27	-0.27%
Dow JONES (US)	49,185.92	18.13	0.04%
FTSE 100	10,332.79	11.70	0.11%
HKSE	25,679.78	245.87	-0.95%
NASDAQ	24,569.70	317.40	-1.28%
Nikkei 225	59,917.46	619.90	-1.02%
NZX 50 Index	12,764.40	110.54	-0.86%
S&P 500	7,122.88	51.03	-0.71%
S&P/ASX 200	8,710.70	10.50	-0.12%
SSE Composite Index	4,078.64	7.71	-0.19%